<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Paranasal sinus cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Paranasal sinus cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Paranasal sinus cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kerstin M Stenson, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel J Haraf, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce E Brockstein, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Brizel, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marvin P Fried, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A range of malignancies can develop in the paranasal (maxillary, ethmoid, sphenoid, frontal) sinuses  (
         <a class="graphic graphic_figure graphicRef78790" href="/z/d/graphic/78790.html" rel="external">
          figure 1
         </a>
         ). Adenocarcinoma and squamous cell carcinoma of the maxillary sinus and ethmoid sinus are the most common of these tumors.
        </p>
        <p>
         The epidemiology, clinical presentation, diagnosis, and management of these tumors are discussed here. Tumors arising in the nasal cavity are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3403.html" rel="external">
          "Cancer of the nasal vestibule"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16861.html" rel="external">
          "Tumors of the nasal cavity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1027917">
         <span class="h1">
          EPIDEMIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cancers arising in the paranasal sinuses are rare, constituting approximately 3 percent of head and neck malignancies [
         <a href="#rid1">
          1
         </a>
         ]. The majority of these tumors arise in the maxillary sinuses, and most of the remainder start in the ethmoid sinuses. Cancers of the sphenoid and frontal sinuses are extremely rare. Paranasal sinus cancers are more frequent in males than in females [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Factors associated with paranasal sinus cancers include [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Occupational exposures
         </strong>
         – Including leather, textile, wood dust, and formaldehyde.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Air pollution
         </strong>
         [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tobacco smoke
         </strong>
         [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viruses
         </strong>
         – Human papillomavirus (HPV) infection has been associated with paranasal sinus cancer, with some evidence suggesting that it may be involved in the malignant degeneration of inverted papilloma of the paranasal sinus, a rare, usually benign condition [
         <a href="#rid5">
          5,6
         </a>
         ]. Correlations have also been suggested between Epstein-Barr virus (EBV) infection and sinonasal tract lymphomas [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately one-half of paranasal malignancies are squamous cell carcinomas, and most of the remainder are adenoid cystic carcinomas, adenocarcinomas, or mucoepidermoid carcinomas [
         <a href="#rid9">
          9,10
         </a>
         ]. A wide range of other tumors can originate in this region, including undifferentiated carcinoma, angiosarcomas, rhabdomyosarcomas, lymphomas, olfactory neuroblastomas (esthesioneuroblastomas), melanomas, and meningiomas. (See
         <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">
          "Pathology of head and neck neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paranasal sinus malignancies tend to be asymptomatic or have nonspecific sinonasal symptoms that may mimic benign disease until they invade adjacent structures. Thus, most patients have advanced disease by the time the diagnosis is established [
         <a href="#rid1">
          1,11,12
         </a>
         ].
        </p>
        <p>
         The most common symptoms include facial or dental pain, nasal obstruction, and epistaxis [
         <a href="#rid1">
          1,12
         </a>
         ]. When symptoms of persistent nasal discharge and epistaxis occur in patients over age 40, cancer of the paranasal sinuses, nasal vestibule, or nasopharynx should be included in the differential diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/3404.html" rel="external">
          "Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         Less common symptoms include cranial neuropathy (especially abnormalities of extraocular movements or trigeminal hypesthesia), chronic sinusitis, facial edema, vision loss, headache, rhinorrhea, and hyposmia. A classic triad of facial asymmetry, palpable/visible tumor in the oral cavity, and visible intranasal tumor occurs in 40 to 60 percent of patients with advanced disease [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Symptoms and signs depend upon the involved site and extent of disease. The bony structures between the nasal cavity, sinuses, orbits, and cranial vaults are thin and offer little resistance to cancer spread.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the ethmoid sinus, locally advanced lesions may extend into the anterior cranial fossa via the cribriform plate or into the orbit through the lamina papyracea. This may result in anosmia or displacement (typically upward and/or outward) of the globe.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the sphenoid sinus, disease may directly extend through the lateral bony wall into the cavernous sinus where cranial nerves III, IV, VI, V1, and V2 travel. It may also invade the middle cranial fossa directly or via the infraorbital nerve. Affected patients may complain of diplopia, blurred vision, proptosis, paresthesias in the distribution of the trigeminal nerve, or trismus if the pterygoid musculature is invaded. Inferior extension into the oral cavity may also cause painful loose teeth.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DIAGNOSIS AND STAGING
         </span>
        </p>
        <p class="headingAnchor" id="H206904222">
         <span class="h2">
          Initial evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of a paranasal sinus malignancy requires tissue for histologic evaluation and the identification of the paranasal sinus as the site of tumor origin. If a paranasal lesion is suspected, the history and physical examination should include close attention to the signs and symptoms (such as cranial nerve involvement) due to orbital extension or base of skull involvement.
        </p>
        <p>
         The limited anatomic access of the paranasal sinuses makes early diagnosis difficult. Endoscopic examination is generally necessary to obtain a biopsy for tissue diagnosis and to assess the extent of local disease, unless there is tumor protruding into the nasal or oral cavity.
        </p>
        <p>
         Lesions involving the maxillary sinus can be biopsied intranasally or through the gingivobuccal sulcus if the tumor extends through the anterior maxilla. Adequate examination and biopsy may require general anesthesia. Ethmoid sinus lesions are biopsied through an endoscopic or transnasal approach in the operating room, as are frontal sinus malignancies via the frontal recess. Frontal sinus trephination is rarely necessary.
        </p>
        <p class="headingAnchor" id="H206904215">
         <span class="h2">
          Staging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imaging studies provide important information for staging and treatment planning. Typically, both computed tomography (CT) and magnetic resonance imaging (MRI) are performed and are complementary in evaluating disease extent and in distinguishing tumor from infection, retained secretions, and granulation of scar tissue. CT offers superior definition of bone and bone invasion, while MRI gives superior soft tissue delineation and allows for visualization of cranial nerves, especially when they are involved with disease [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
         The eighth (2017) tumor, node, metastasis (TNM) staging system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) defines separate T staging for tumors of the maxillary and ethmoid sinuses  (
         <a class="graphic graphic_table graphicRef110768" href="/z/d/graphic/110768.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid16">
          16
         </a>
         ]. There is no standard staging system for frontal or sphenoid sinus tumors. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer"
         </a>
         .)
        </p>
        <p>
         Regional lymph node metastases are uncommon with early-stage disease that is confined to the sinuses [
         <a href="#rid17">
          17
         </a>
         ]. The retropharyngeal nodes comprise the first echelon of lymphatic drainage for sinus malignancies. Other regional nodes that are commonly involved are the periparotid, level 1B, and level 2 nodes  (
         <a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ]. The incidence of lymph node involvement increases as tumors extend locally to adjacent sites, especially with extension into the oral cavity. Interestingly, one large series found higher rates of cervical lymph node involvement with T2 rather than T3 or T4 tumors of squamous cell histology [
         <a href="#rid11">
          11
         </a>
         ]. This finding is due to the unique staging of maxillary sinus cancer, where T2 lesions are those that extend into the hard palate or nasal cavity. These areas have a richer lymphatic plexus and act more like oral cavity cancers, with a higher rate of occult metastases.
        </p>
        <p>
         Distant metastases are uncommon at presentation. The lung, liver, and bone are the sites most frequently involved when distant metastases occur after treatment or are present at diagnosis. Chest imaging with CT can be considered clinically indicated, while positron emission tomography (PET)/CT should be considered for stage III or IV disease at presentation [
         <a href="#rid11">
          11,19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          SQUAMOUS CELL CARCINOMA AND ADENOCARCINOMA
         </span>
        </p>
        <p class="headingAnchor" id="H262658880">
         <span class="h2">
          General approach to management
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no randomized trials that define the optimal treatment for paranasal cancers because of the rarity of these tumors and because of their heterogeneity in both histology and site of origin. The available data are derived from single-institution, observational series. The approach described here is consistent with guidelines from the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Paranasal sinus cancers generally invade locally early in their natural history and have a high tendency for local recurrence. Local recurrence rates following resection are high in the absence of postoperative radiation therapy (RT), even when the original resection is thought to have been complete.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with early (stage I/II) disease  (
         <a class="graphic graphic_table graphicRef110768" href="/z/d/graphic/110768.html" rel="external">
          table 1
         </a>
         ), complete surgical resection is the initial step in management. Postoperative RT is indicated for those who are at increased risk of local recurrence (eg, positive or uncertain surgical margins, unfavorable histology, perineural invasion). (See
         <a class="local">
          'Surgery'
         </a>
         below and
         <a class="local">
          'Radiation therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with locally advanced (stage III/IV) disease, initial surgical resection is preferred as the initial therapy. Postoperative adjuvant RT is indicated because of the high risk of local recurrence. (See
         <a class="local">
          'Surgery'
         </a>
         below and
         <a class="local">
          'Radiation therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RT or chemoradiotherapy are alternatives for patients who are not candidates for a definitive surgery.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical resection is indicated for all operable adenocarcinomas and squamous cell carcinomas arising in the maxillary or ethmoid sinuses (T1 to T4), regardless of nodal status.
        </p>
        <p>
         Resection is often limited by tumor involvement that can result in damage to critical structures such as the eyes, brain, and cranial nerves. Advances in surgical techniques have resulted in better functional reconstructions and improved quality of life [
         <a href="#rid22">
          22
         </a>
         ], and the decision of whether or not to operate depends upon the balance between survival, morbidity, and function [
         <a href="#rid23">
          23-25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6302814">
         <span class="h3">
          Management of the orbit
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative computed tomography (CT) and magnetic resonance imaging (MRI) are essential to evaluate the extent of disease and orbital involvement and to plan the surgical approach. Tumor adjacent to the periorbita (the dense periosteum surrounding the globe) was the most sensitive predictor of orbital invasion for both CT and MRI in a small study of patients with advanced sinus malignancy [
         <a href="#rid26">
          26-28
         </a>
         ]. A European position paper on endoscopic management of paranasal sinus tumors suggested that orbital fat signal-suppressed (short tau inversion recovery [STIR]) images by MRI may improve detection of orbital fat infiltration [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Three stages of orbital invasion have been described: grade I, destruction of the medial orbital wall; grade II, invasion of the periorbital fat, extraconal; and grade III, invasion of the medial rectus, optic nerve, bulb, or eyelid skin, which implies breaching of the periorbita/periosteum. Orbital exenteration has been advocated only for those patients who present with grade III invasion; however, frozen section at the time of surgery is often necessary to confirm whether or not tumor has transgressed the periosteum [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Orbital exenteration does not improve survival for patients with advanced sinus malignancy that does not completely transgress the dense periorbita [
         <a href="#rid31">
          31
         </a>
         ]. Although recurrence in the orbit has been associated with poor prognosis [
         <a href="#rid32">
          32-34
         </a>
         ], most head and neck surgeons favor orbital preservation with periosteal resection in the case of incomplete periosteal invasion since this yields comparable survival and can maintain a functional eye [
         <a href="#rid31">
          31,32,35-37
         </a>
         ]. Orbital exenteration is indicated for gross transgression of the periorbita into the intraconal fat or orbital apex. Studies also suggest that the orbit-preservation rate can be improved with strategies that incorporate neoadjuvant chemotherapy [
         <a href="#rid38">
          38-41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6302735">
         <span class="h3">
          Endoscopic resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advances in surgical technique have led to an increasing use of image-guided endoscopic approaches for the resection of sinonasal tumors [
         <a href="#rid22">
          22
         </a>
         ]. These techniques have largely replaced open approaches in many academic centers.
        </p>
        <p>
         Image-guided endoscopic techniques are a multidisciplinary collaboration of otolaryngologists and neurosurgeons. They provide superior visualization, with angled endoscopes affording exposure around anatomic corners. The endoscopic method employs piecemeal tumor removal and was initially criticized for its inability to achieve an en bloc resection. Clear surgical margins (regardless of the surgical method) are a critical factor for tumor control, and both open and endoscopic techniques appear equally effective in this aspect. Endoscopic sinus surgery has been used both alone and in combination with open craniofacial surgery.
        </p>
        <p>
         These endoscopic approaches may offer significant advantages in terms of a lower frequency of surgical complications and decreased morbidity. Advantages include lack of facial incisions, craniotomies, or facial bone osteotomies; decreased neurovascular structure manipulation; early tumor devascularization; access to deeply seated lesions; decreased hospital stay and pain; and faster recovery [
         <a href="#rid29">
          29
         </a>
         ]. Brain retraction is avoidable, so postoperative brain edema and possible encephalomalacia are circumvented [
         <a href="#rid42">
          42
         </a>
         ]. Nasal crusting can be a complication of both endoscopic and open approaches. This is related to disruption of the sinus mucosal lining as well as to postoperative radiation.
        </p>
        <p>
         Endoscopic sinus surgery has also been utilized for palliation of symptoms (epistaxis, nasal obstruction, etc) in advanced sinonasal malignancies [
         <a href="#rid43">
          43
         </a>
         ]. Contraindications to a pure endoscopic approach include tumors with extensive dural involvement or extension into facial or orbital soft tissues.
        </p>
        <p>
         Several series that included patients with a variety of histologic tumor types have found that endoscopic techniques can be applied to patients with locally advanced lesions [
         <a href="#rid44">
          44,45
         </a>
         ]. Similar oncologic results have been documented in numerous studies compared with traditional open approaches. As an example, one study that used propensity score analysis to control for differences in patient comorbidities and tumor size reported shorter lengths of stay but similar recurrence rates and survival rates with endoscopic approaches when compared with open approaches [
         <a href="#rid46">
          46
         </a>
         ]. In another cohort study, patients undergoing endoscopic resection reported improved sinus-specific quality of life that was sustained over two years [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Reconstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of surgical and prosthetic reconstruction is to replace the form and function of facial and anterior skull base defects caused by surgery. Advances in tissue transfer techniques (particularly microvascular free flaps) provide reconstructive options in addition to maxillofacial prostheses. Optimal esthetic, functional, and quality of life outcomes are superior with combined approaches rather than single techniques [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Key issues with the management of maxillectomy defects include reconstruction of the orbital floor in order to support globe position, reconstruction of the palatal surface to separate nasal contents and to provide framework for dental rehabilitation, and reestablishment of facial symmetry [
         <a href="#rid27">
          27
         </a>
         ]. Contemporary reconstruction techniques utilize custom 3D modeling (virtual surgical planning [VSP]) as well as intraoperative, image-guided navigation to ascertain position and symmetry [
         <a href="#rid49">
          49
         </a>
         ]. For patients who have undergone orbital exenteration/clearance, temporalis muscle or temporoparietalis flaps can be used to line the cavity. (See
         <a class="medical medical_review" href="/z/d/html/3376.html" rel="external">
          "Management of acquired maxillary and hard palate defects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3396.html" rel="external">
          "Mandibular and palatal reconstruction in patients with head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6302598">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serious postoperative complications associated with craniofacial resection can include meningitis, hemorrhage, wound infection and abscess, cerebrospinal fluid leak, pneumocephalus, trismus, and blindness [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p>
         Surgical mortality and complication rates can be significant. A multi-institution analysis of 1193 patients who underwent open craniofacial resection observed postoperative mortality and complication rates of 5 and 36 percent, respectively [
         <a href="#rid51">
          51
         </a>
         ]. The risk of complications and mortality is increased substantially for patients older than 70 years [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         State-of-the-art image-guided endoscopic/endonasal approaches to skull base malignancies are associated with decreased postoperative morbidity and mortality. In a review of 800 patients, cerebrospinal fluid leak was the most common complication (16 percent). All but one patient was repaired endoscopically. The overall incidence of cerebrospinal fluid leak in this series decreased significantly with the use of vascularized skull base reconstruction. Overall mortality was 0.9 percent [
         <a href="#rid53">
          53
         </a>
         ]. Another study of 1000 patients who underwent endoscopic skull base surgery showed an overall infection rate of 1.8 percent [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6296085">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paranasal sinus cancers have a high tendency for local recurrence in the absence of postoperative RT, even when the original resection was thought to be complete. Although there are no randomized trials, postoperative RT is widely used and has been effective in decreasing the incidence of local recurrence [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         The use of RT as primary therapy without surgery is generally limited to patients with unresectable disease as well as to those who are medically unsuited for major surgery.
        </p>
        <p class="headingAnchor" id="H9244083">
         <span class="h3">
          Contemporary RT techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advances in RT techniques have led to the development of highly conformal techniques that permit the delivery of therapeutic doses of radiation to paranasal sinus tumors while minimizing the dose of radiation to uninvolved normal tissues.
        </p>
        <p>
         Widely used conformal techniques include three-dimensional conformal RT and intensity-modulated RT [
         <a href="#rid55">
          55
         </a>
         ]. Charged particle irradiation (proton beam, carbon ion) may offer additional advantages for delivering maximal tumor doses while minimizing radiation to the retina and brain compared with photon-based therapy [
         <a href="#rid56">
          56,57
         </a>
         ]. However, there are no prospective comparisons, and the data in these retrospective analyses often used older RT techniques. (See
         <a class="medical medical_review" href="/z/d/html/3406.html" rel="external">
          "General principles of radiation therapy for head and neck cancer", section on 'Three-dimensional conformal RT'
         </a>
         .)
        </p>
        <p>
         For patients who have undergone complete resection of their tumor and have adverse prognostic features (ie, perineural infiltration or adenoid cystic carcinoma), the dose of postoperative radiation is generally approximately 60 Gy when given on a once-daily schedule. For patients with positive tumor margins and for those that are unresectable, the prescribed doses are approximately 66 and 70 Gy, respectively, when given in 2 Gy fractions once daily. There are no randomized trials that define the dose of radiation in these patient populations, and these schedules are based upon more-extensive data from other head and neck cancers. (See
         <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">
          "Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations", section on 'Paradigms of dose and fractionation modification'
         </a>
         .)
        </p>
        <p>
         Concomitant chemotherapy and radiation is an alternative to RT alone in those patient with unresectable disease or adverse prognostic features (perineural infiltration, positive margins). (See
         <a class="local">
          'Chemotherapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6301996">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of radiation retinopathy is strongly correlated with the dose of radiation to the retina.
        </p>
        <p>
         This relationship was analyzed in a study of 186 patients who received a significant dose of radiation to the retina as part of curative therapy for head and neck cancer. Approximately two-thirds of the patients in that series were treated for cancer of the nasal cavity or paranasal sinuses, and most of the remainder had a primary nasopharyngeal cancer [
         <a href="#rid58">
          58
         </a>
         ]. Radiation retinopathy developed in 31 eyes in 30 patients, resulting in blindness in 26 and decreased vision in the other five eyes. Radiation retinopathy developed in 25 of the 30 eyes that received 60 Gy or more to the retina. In contrast, only 3 of 72 eyes (4 percent) that received less than 50 Gy developed radiation retinopathy.
        </p>
        <p>
         Observational series indicate that these conformal techniques have comparable efficacy to earlier series but with a substantially decreased incidence of blindness and other serious eye complications [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As an example, 85 patients with paranasal sinus tumors were treated postoperatively over an 18-year period at a single institution [
         <a href="#rid59">
          59
         </a>
         ]. Among the 53 patients treated with contemporary planning and conformal treatment techniques, there were no grade 3 or worse eye complications. Disease control was comparable to other series.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another series, 84 patients were treated with intensity-modulated RT, including 73 immediately following surgery and 11 for a local recurrence [
         <a href="#rid60">
          60
         </a>
         ]. The five-year rates of overall and disease-specific survival were 59 and 67 percent, respectively, which was similar to that in other series. There were no cases of blindness, although one patient developed radiation-induced retinopathy and neovascular glaucoma.
        </p>
        <p>
        </p>
        <p>
         Other serious complications of RT can occur include osteoradionecrosis and brain necrosis. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation", section on 'Brain tissue necrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6296135">
         <span class="h2">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemotherapy has been incorporated as a component of multimodality therapy with RT and/or surgery in a variety of ways. However, there are no randomized trials in patients with paranasal sinus cancers, and no definitive conclusions can be drawn about the impact of chemotherapy on outcomes.
        </p>
        <p>
         Based on results in other squamous head and neck cancers, our approach is to consider adding chemotherapy to RT in two settings: for unresectable but curative-intent therapy in good performance status patients, and in the postoperative setting with positive margins or extracapsular extension of tumor. (See
         <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">
          "Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"
         </a>
         .)
        </p>
        <p>
         Several relatively large series provide an illustration of the range of outcomes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective study, cisplatin-based chemotherapy was given to 49 patients, including 38 with T3 or T4 disease  (
         <a class="graphic graphic_table graphicRef110768" href="/z/d/graphic/110768.html" rel="external">
          table 1
         </a>
         ), all of whom had resectable, previously untreated disease [
         <a href="#rid61">
          61
         </a>
         ]. Chemotherapy was followed by surgery and postoperative RT in 19 of 21 responders and 23 of 28 nonresponders. The three-year overall and event-free survival rates were 69 and 57 percent, respectively. An earlier, smaller series using chemotherapy as induction yielded similar results [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 39 patients with stage IVB disease  (
         <a class="graphic graphic_table graphicRef110768" href="/z/d/graphic/110768.html" rel="external">
          table 1
         </a>
         ), 35 patients were managed with chemotherapy plus definitive RT and four were treated with definitive RT alone [
         <a href="#rid63">
          63
         </a>
         ]. Management did not include surgical resection. With a median follow-up of over seven years, the five-year disease-free and overall survival rates were approximately 15 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another series reported the results of 46 patients treated with induction chemotherapy followed by surgery and RT or concomitant chemotherapy with RT in 22 patients [
         <a href="#rid64">
          64
         </a>
         ]. The remainder had definitive RT or concomitant chemotherapy and RT with surgery for salvage. Overall 67 percent had a partial to complete response, 9 percent had stable disease, and 24 percent had progressive disease. The two-year survival was 77 percent for patients who responded and 36 percent for those with progressive disease on induction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 41 patients with stage III, IVA, and IVB disease, patients were managed with surgery plus postoperative RT or chemoradiation, or concomitant chemoradiation without surgery [
         <a href="#rid65">
          65
         </a>
         ]. With a median follow-up of over six years, the median progression-free survival duration was 45 months, and the five-year overall survival rate was 65 percent. Outcomes were better in those patients who had undergone surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective review of 179 Italian patients treated between 1996 and 2000, chemotherapy was used in the induction setting or concomitant setting (three doses of high-dose
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ). Chemotherapy used in this setting was associated with a nonstatistically significant benefit in overall survival of mostly T4N0 patients [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6303274">
         <span class="h2">
          Management of the neck
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cervical lymph node metastases are uncommon at presentation. In a series of 704 consecutive patients with paranasal sinus cancer treated over a 25 year period, 5 percent had cervical node disease at presentation [
         <a href="#rid11">
          11
         </a>
         ]. The cumulative incidence of lymph node involvement either at presentation or within five years was approximately 14 percent.
        </p>
        <p>
         Neck dissection and postoperative RT are recommended for all patients with cervical lymph node involvement, either at presentation or subsequently, if relapse occurs in the cervical lymph nodes. (See
         <a class="medical medical_review" href="/z/d/html/97170.html" rel="external">
          "Management of the neck following definitive radiotherapy with or without chemoradiotherapy in head and neck squamous cell carcinoma"
         </a>
         .)
        </p>
        <p>
         Prophylactic treatment (neck dissection or RT) of the N0 lymph-node-negative  (
         <a class="graphic graphic_table graphicRef110768" href="/z/d/graphic/110768.html" rel="external">
          table 1
         </a>
         ) neck is controversial [
         <a href="#rid22">
          22
         </a>
         ]. For patients who present without neck node involvement, the risk of subsequent recurrence in the neck has ranged from 3 to approximately 30 percent in different series [
         <a href="#rid67">
          67
         </a>
         ]. Although prophylactic neck dissection or irradiation can reduce the incidence of neck recurrence, most such relapses are associated with other sites of involvement, and it is not clear that there is an impact on overall survival.
        </p>
        <p>
         Factors weighing against prophylactic treatment include the low incidence of subsequent relapse, the observation that most such relapses are associated with other sites of involvement, and the lack of impact on overall survival from prophylactic treatment.
        </p>
        <p>
         For patients who present with a T3 or T4 primary lesion, the risk of nodal involvement at presentation or subsequent neck node relapse increases substantially. Prophylactic/elective selective neck dissection has acceptable morbidity and provides valuable staging and prognostic information. In a Surveillance, Epidemiology, and End Results (SEER) database study of 927 patients with maxillary sinus squamous cell carcinoma and clinically negative lymph nodes, the five-year hazard of death was reduced by elective neck dissection for those with T3 tumors [
         <a href="#rid68">
          68
         </a>
         ]. Thus, our approach is to suggest prophylactic neck treatment for patients with T3 or T4 disease. For patients who will be managed with definitive resection of the primary site, we suggest ipsilateral neck dissection, and for those who are managed with definitive RT (with or without chemotherapy), we suggest prophylactically irradiating the ipsilateral node-negative (N0) neck.
        </p>
        <p class="headingAnchor" id="H6296142">
         <span class="h2">
          Recurrent and metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with locoregionally recurrent disease are treated with multimodality therapy, including resection, reirradiation, and concurrent chemotherapy and RT. Distant metastatic disease is typically treated with chemotherapy alone. There are insufficient data to differentiate the management of these patients from that of other head and neck cancer cases [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3373.html" rel="external">
          "Treatment of locally recurrent squamous cell carcinoma of the head and neck"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3364.html" rel="external">
          "Treatment of metastatic and recurrent head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6296149">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Results in large series vary depending upon case mix and the time period that was analyzed. In general, five-year overall survival rates around 50 percent have been reported [
         <a href="#rid11">
          11,12,70-75
         </a>
         ], with significant variation depending upon stage and histology  (
         <a class="graphic graphic_table graphicRef57100 graphicRef66398" href="/z/d/graphic/57100.html" rel="external">
          table 2A-B
         </a>
         ). Factors associated with a better prognosis include lower T stage, the absence of lymph node involvement, and adenocarcinoma rather than squamous cell carcinoma or undifferentiated carcinoma. Primary tumors arising in the maxillary sinus appear to have a better prognosis than those arising in the ethmoid sinus. In a SEER database review, tumors of the nasal cavity had the highest five-year disease-specific survival (67.1 percent) while tumors of overlapping sinus sites had the lowest (37.6 percent) [
         <a href="#rid76">
          76,77
         </a>
         ].
        </p>
        <p>
         Like many other cancer sites, there are racial disparities in sinonasal carcinoma. In a review of over 4000 patients, Black individuals and Hispanic individuals were at risk for poorer disease-specific survival [
         <a href="#rid78">
          78
         </a>
         ]. Others found that that difference in racial survival in sinonasal cancer is related to two factors: overall stage and the use of standard-of-care treatment appropriate for stage [
         <a href="#rid78">
          78,79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6296156">
         <span class="h2">
          Posttreatment follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be monitored for evidence of recurrence following treatment, although a survival benefit has not been demonstrated for posttreatment surveillance  (
         <a class="graphic graphic_table graphicRef54259" href="/z/d/graphic/54259.html" rel="external">
          table 3
         </a>
         ). In general, the intensity of follow-up is greatest in the first two to three years, which is the period of greatest risk for disease recurrence. (See
         <a class="medical medical_review" href="/z/d/html/3379.html" rel="external">
          "Posttreatment surveillance of squamous cell carcinoma of the head and neck"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          OTHER TUMOR TYPES
         </span>
        </p>
        <p class="headingAnchor" id="H4210195059">
         <span class="h2">
          Human papilloma virus-related multiphenotypic sinonasal carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human papillomavirus (HPV)-related multiphenotypic sinonasal carcinoma (HMSC) is a sinonasal malignancy that displays strong and diffuse p16 positivity as well as high-risk HPV, usually HPV 33. HMSC has clinical and histologic features similar to those seen with sinonasal adenoid cystic cancer [
         <a href="#rid80">
          80,81
         </a>
         ]. (See
         <a class="local">
          'Adenoid cystic carcinoma'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Adenoid cystic carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adenoid cystic carcinomas can arise in the minor salivary glands of the paranasal sinuses. These tumors tend to spread locally through bony destruction and perineural and perivascular invasion. Adenoid cystic carcinomas have characteristically high rates of local recurrence and distant metastases (typically lung and bone), which can occur as late as 10 to 20 years following initial treatment. (See
         <a class="medical medical_review" href="/z/d/html/3400.html" rel="external">
          "Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3377.html" rel="external">
          "Salivary gland tumors: Treatment of locoregional disease"
         </a>
         .)
        </p>
        <p>
         Primary surgery followed by radiation therapy (RT) is recommended [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6304283">
         <span class="h2">
          Sinonasal undifferentiated carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sinonasal undifferentiated carcinoma (SNUC) is a rare, poorly differentiated, rapidly growing malignancy that arises from the mucosa of the nasal cavity or paranasal sinuses. (See
         <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">
          "Pathology of head and neck neoplasms", section on 'Sinonasal undifferentiated carcinoma'
         </a>
         .)
        </p>
        <p>
         SNUC is associated with a poor prognosis, generally presenting with locally advanced disease and a high frequency of distant metastases, even when local disease control can be obtained. There are no clinical trials to guide treatment for patients with SNUC, and data are derived either from small single-institution series, meta-analyses of such reports, or larger database studies. (See
         <a class="medical medical_review" href="/z/d/html/16861.html" rel="external">
          "Tumors of the nasal cavity", section on 'Sinonasal undifferentiated and small cell carcinoma'
         </a>
         .)
        </p>
        <p>
         As an example, a National Cancer Database (NCDB) study identified 435 patients with SNUC between 2004 and 2012 [
         <a href="#rid83">
          83
         </a>
         ]. Approximately 60 percent of cases arose in the paranasal sinuses, the remainder arose in the nasal cavity; only 6 percent had T1 or T2 lesions at presentation. The cumulative five-year survival rate was 42 percent. Multivariate analysis indicated that trimodality therapy (optimal surgical resection combined with chemoradiotherapy) was associated with better outcomes than surgery or surgery plus RT alone. A similar study of 460 patients using the NCDB found the best survival in those undergoing surgery with postoperative chemoradiotherapy [
         <a href="#rid84">
          84
         </a>
         ]. However, no patient undergoing surgery and adjuvant treatment with positive surgical margins survived to five years. These results suggest that surgery should be limited to patients in whom negative margins can be reliably obtained.
        </p>
        <p>
         Single-institution series support a role for trimodality therapy including maximal surgical resection and adequate radiation dosing [
         <a href="#rid85">
          85-89
         </a>
         ]. The optimal sequencing of these therapies is not known and may differ with patient presentation. Some experts offer surgical resection followed by chemoradiotherapy, while others offer induction chemotherapy followed by surgery and/or chemoradiotherapy. As an example, one observational study suggested that response to induction chemotherapy could be used to select patients for definitive therapy with either surgery of chemoradiotherapy [
         <a href="#rid90">
          90
         </a>
         ]. This strategy has also been proposed for tumors at all head and neck sites, not just the paranasal sinus, with the vast majority of supporting data in patients with squamous cell carcinoma. However, it is a potentially risky strategy for patients with T1 and T2 primaries, especially SNUCs, which often do not respond to drug therapy, as it runs the risk of converting resectable disease into unresectable disease for nonresponders to chemotherapy. Further details on the use of induction chemotherapy in SNUC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16861.html" rel="external">
          "Tumors of the nasal cavity", section on 'Induction chemotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Inverted papilloma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inverted papilloma is a benign, locally aggressive neoplasm that is associated with squamous cell carcinoma in approximately 5 percent of cases [
         <a href="#rid91">
          91,92
         </a>
         ].
        </p>
        <p>
         Treatment for inverted papilloma is primarily surgical resection, which is increasingly accomplished using endoscopic approaches [
         <a href="#rid93">
          93-95
         </a>
         ]. RT is added if it is associated with squamous cell carcinoma or if it is incompletely resected. Local recurrence is common. (See
         <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">
          "Pathology of head and neck neoplasms", section on 'Schneiderian papillomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6304224">
         <span class="h2">
          Olfactory neuroblastoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Olfactory neuroblastomas, also known as esthesioneuroblastomas, arise from the olfactory epithelium and invade into the paranasal sinuses. The management of olfactory neuroblastoma is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5183.html" rel="external">
          "Olfactory neuroblastoma (esthesioneuroblastoma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphoma of the paranasal sinuses is most commonly a diffuse large B-cell lymphoma, though nasal-type natural killer (NK)/T-cell non-Hodgkin lymphoma is also seen. Combination chemotherapy and RT is suggested; the role of central nervous system prophylaxis is debated [
         <a href="#rid96">
          96-99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">
          "Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Head and neck'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Melanoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sinonasal melanoma of the paranasal sinus has a particularly poor prognosis [
         <a href="#rid100">
          100
         </a>
         ]. Primary treatment is surgical, and postoperative RT is sometimes used for close or positive margins [
         <a href="#rid101">
          101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16904.html" rel="external">
          "Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment", section on 'Mucosal melanoma of the head and neck'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2910796017">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">
          "Society guideline links: Head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H180178974">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – Paranasal sinus cancers are rare tumors that encompass multiple histologies. (See
         <a class="local">
          'Epidemiology and risk factors'
         </a>
         above and
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Paranasal sinus cancers tend to be asymptomatic or have nonspecific sinonasal symptoms that mimic benign disease until they invade adjacent structures. Most patients have advanced disease by the time the diagnosis is established. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to management
         </strong>
         – Treatment needs to incorporate information about both histology and anatomic site of origin. (See
         <a class="local">
          'Pathology'
         </a>
         above and
         <a class="local">
          'General approach to management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of adenocarcinoma and squamous cell carcinoma
         </strong>
         – Adenocarcinoma and squamous cell carcinoma of the maxillary sinus and ethmoid sinus are the most common of these tumors. Aggressive surgical resection remains the mainstay of treatment. Combined modality approaches (radiation therapy [RT], chemotherapy) have been added to improve local control for patients at high risk of recurrence. (See
         <a class="local">
          'Squamous cell carcinoma and adenocarcinoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with early (stage I or II) paranasal sinus cancer, we recommend surgical resection (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). For patients who are not candidates for a major surgical procedure, definitive intensity-modulated RT is an appropriate alternative. While proton therapy has some theoretical advantages in dose distribution, there are little data to support widespread use. We suggest postoperative RT for patients with T1 and T2 lesions with close or positive margins, high-grade histology, and other adverse prognostic features, including perineural, lymphatic, and perivascular invasion (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with locoregionally advanced (stage III and IV) paranasal sinus cancer, we recommend a combined modality approach that includes surgical resection followed by adjuvant RT, rather than surgical resection or RT alone (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with stage III and IV disease and a clinically negative neck (N0), we suggest prophylactic treatment of the neck nodes with either lymph node dissection or RT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Surgery'
         </a>
         above and
         <a class="local">
          'Radiation therapy'
         </a>
         above and
         <a class="local">
          'Management of the neck'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with clinical involvement of the cervical lymph nodes, we recommend neck dissection with postoperative RT (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Management of the neck'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Induction and/or concurrent chemoradiation therapy approaches may have a role in the management of patients with paranasal sinus cancer. However data are too limited to make definitive recommendations, and such treatment should be undertaken only after joint surgical, radiation oncology, and medical oncology evaluation. (See
         <a class="local">
          'Chemotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of other histologies
         </strong>
         – Management of patients with other tumor histologies is tumor specific. (See
         <a class="local">
          'Other tumor types'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Llorente JL, López F, Suárez C, Hermsen MA. Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol 2014; 11:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum 2012; 100:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calderón-Garcidueñas L, Delgado R, Calderón-Garcidueñas A, et al. Malignant neoplasms of the nasal cavity and paranasal sinuses: a series of 256 patients in Mexico City and Monterrey. Is air pollution the missing link? Otolaryngol Head Neck Surg 2000; 122:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng W, McLaughlin JK, Chow WH, et al. Risk factors for cancers of the nasal cavity and paranasal sinuses among white men in the United States. Am J Epidemiol 1993; 138:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JY, Yoon JK, Citardi MJ, et al. The prevalence of human papilloma virus infection in sinonasal inverted papilloma specimens classified by histological grade. Am J Rhinol 2007; 21:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alos L, Moyano S, Nadal A, et al. Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer 2009; 115:2701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng YF, Wu QL, Zong YS. Correlation of immunophenotype of sinonasal non-Hodgkin's lymphoma to Epstein-Barr virus infection. Ai Zheng 2007; 26:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitarnun W, Suwiwat S, Pradutkanchana J. Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand. Asian Pac J Cancer Prev 2006; 7:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012; 34:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youlden DR, Cramb SM, Peters S, et al. International comparisons of the incidence and mortality of sinonasal cancer. Cancer Epidemiol 2013; 37:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantù G, Bimbi G, Miceli R, et al. Lymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment. Arch Otolaryngol Head Neck Surg 2008; 134:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guntinas-Lichius O, Kreppel MP, Stuetzer H, et al. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol 2007; 33:222.
          </a>
         </li>
         <li class="breakAll">
          Comprehensive Management of Head and Neck Tumors, 2nd ed, Thawley SE, Panje WR, Batsakis JG, et al (Eds), WB Saunders, Philadelphia 1999.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loevner LA, Sonners AI. Imaging of neoplasms of the paranasal sinuses. Neuroimaging Clin N Am 2004; 14:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Das S, Kirsch CF. Imaging of lumps and bumps in the nose: a review of sinonasal tumours. Cancer Imaging 2005; 5:167.
          </a>
         </li>
         <li class="breakAll">
          Kraus DH, Lydiatt WM, Patel SG, et al. Nasal cavity and paranasal sinuses. In: American Joint Committee on Cancer, 8th ed, Amin MB (Ed), Springer, New York 2017. p.137.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homma A, Hayashi R, Matsuura K, et al. Lymph node metastasis in t4 maxillary sinus squamous cell carcinoma: incidence and treatment outcome. Ann Surg Oncol 2014; 21:1706.
          </a>
         </li>
         <li class="breakAll">
          Cummings Otolaryngology-Head and Neck Surgery, 4th ed, Cummings CW Jr, Haughey BH, Thomas JR (Eds), Mosby, St. Louis 2004.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogaerts S, Vander Poorten V, Nuyts S, et al. Results of endoscopic resection followed by radiotherapy for primarily diagnosed adenocarcinomas of the paranasal sinuses. Head Neck 2008; 30:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen EP, Keus RB, Hilgers FJ, et al. Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys 2000; 48:27.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (Accessed on January 04, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robbins KT, Ferlito A, Silver CE, et al. Contemporary management of sinonasal cancer. Head Neck 2011; 33:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari M, Orlandi E, Bossi P. Sinonasal cancers treatments: state of the art. Curr Opin Oncol 2021; 33:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentini V, Terenzi V, Battisti A, et al. Management of clinically negative neck in maxillary carcinoma. J Craniofac Surg 2010; 21:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filtenborg MV, Lilja-Fischer JK, Sharma MB, et al. Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA. Acta Oncol 2021; 60:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HJ, Lee TH, Lee HS, et al. Periorbita: computed tomography and magnetic resonance imaging findings. Am J Rhinol 2006; 20:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suárez C, Ferlito A, Lund VJ, et al. Management of the orbit in malignant sinonasal tumors. Head Neck 2008; 30:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisen MD, Yousem DM, Loevner LA, et al. Preoperative imaging to predict orbital invasion by tumor. Head Neck 2000; 22:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lund VJ, Stammberger H, Nicolai P, et al. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl 2010; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iannetti G, Valentini V, Rinna C, et al. Ethmoido-orbital tumors: our experience. J Craniofac Surg 2005; 16:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrau RL, Segas J, Nuss DW, et al. Squamous cell carcinoma of the sinonasal tract invading the orbit. Laryngoscope 1999; 109:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard DJ, Lund VJ, Wei WI. Craniofacial resection for tumors of the nasal cavity and paranasal sinuses: a 25-year experience. Head Neck 2006; 28:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Tuyl R, Gussack GS. Prognostic factors in craniofacial surgery. Laryngoscope 1991; 101:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCaffrey TV, Olsen KD, Yohanan JM, et al. Factors affecting survival of patients with tumors of the anterior skull base. Laryngoscope 1994; 104:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiwari R, van der Wal J, van der Waal I, Snow G. Studies of the anatomy and pathology of the orbit in carcinoma of the maxillary sinus and their impact on preservation of the eye in maxillectomy. Head Neck 1998; 20:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imola MJ, Schramm VL Jr. Orbital preservation in surgical management of sinonasal malignancy. Laryngoscope 2002; 112:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Essig GF, Newman SA, Levine PA. Sparing the eye in craniofacial surgery for superior nasal vault malignant neoplasms: analysis of benefit. Arch Facial Plast Surg 2007; 9:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castelnuovo P, Lambertoni A, Sileo G, et al. Critical review of multidisciplinary approaches for managing sinonasal tumors with orbital involvement. Acta Otorhinolaryngol Ital 2021; 41:S76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatelet F, Simon F, Bedarida V, et al. Surgical Management of Sinonasal Cancers: A Comprehensive Review. Cancers (Basel) 2021; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari M, Migliorati S, Tomasoni M, et al. Sinonasal cancer encroaching the orbit: Ablation or preservation? Oral Oncol 2021; 114:105185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelmeguid AS, Teeramatwanich W, Roberts DB, et al. Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer 2021; 127:1788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyderman CH, Carrau RL, Kassam AB, et al. Endoscopic skull base surgery: principles of endonasal oncological surgery. J Surg Oncol 2008; 97:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabaee A, Nyquist G, Anand VK, et al. Palliative endoscopic surgery in advanced sinonasal and anterior skull base neoplasms. Otolaryngol Head Neck Surg 2010; 142:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su SY, Kupferman ME, DeMonte F, et al. Endoscopic resection of sinonasal cancers. Curr Oncol Rep 2014; 16:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins TS, Thorp B, Rawlings BA, Han JK. Outcome results of endoscopic vs craniofacial resection of sinonasal malignancies: a systematic review and pooled-data analysis. Int Forum Allergy Rhinol 2011; 1:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farquhar D, Kim L, Worrall D, et al. Propensity score analysis of endoscopic and open approaches to malignant paranasal and anterior skull base tumor outcomes. Laryngoscope 2016; 126:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glicksman JT, Parasher AK, Brooks SG, et al. Sinonasal quality of life after endoscopic resection of malignant sinonasal and skull base tumors. Laryngoscope 2018; 128:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Futran ND, Mendez E. Developments in reconstruction of midface and maxilla. Lancet Oncol 2006; 7:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang YF, Liang J, He Z, et al. Orbital floor symmetry after maxillectomy and orbital floor reconstruction with individual titanium mesh using computer-assisted navigation. J Plast Reconstr Aesthet Surg 2020; 73:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solero CL, DiMeco F, Sampath P, et al. Combined anterior craniofacial resection for tumors involving the cribriform plate: early postoperative complications and technical considerations. Neurosurgery 2000; 47:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganly I, Patel SG, Singh B, et al. Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study. Head Neck 2005; 27:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganly I, Gross ND, Patel SG, et al. Outcome of craniofacial resection in patients 70 years of age and older. Head Neck 2007; 29:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassam AB, Prevedello DM, Carrau RL, et al. Endoscopic endonasal skull base surgery: analysis of complications in the authors' initial 800 patients. J Neurosurg 2011; 114:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kono Y, Prevedello DM, Snyderman CH, et al. One thousand endoscopic skull base surgical procedures demystifying the infection potential: incidence and description of postoperative meningitis and brain abscesses. Infect Control Hosp Epidemiol 2011; 32:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brizel DM, Light K, Zhou SM, Marks LB. Conformal radiation therapy treatment planning reduces the dose to the optic structures for patients with tumors of the paranasal sinuses. Radiother Oncol 1999; 51:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol 2014; 15:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koto M, Demizu Y, Saitoh JI, et al. Definitive Carbon-Ion Radiation Therapy for Locally Advanced Sinonasal Malignant Tumors: Subgroup Analysis of a Multicenter Study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS). Int J Radiat Oncol Biol Phys 2018; 102:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monroe AT, Bhandare N, Morris CG, Mendenhall WM. Preventing radiation retinopathy with hyperfractionation. Int J Radiat Oncol Biol Phys 2005; 61:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys 2007; 67:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madani I, Bonte K, Vakaet L, et al. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009; 73:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Licitra L, Locati LD, Cavina R, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol 2003; 14:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MM, Vokes EE, Rosen A, et al. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am 1999; 5:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe BS, Nelson CJ, Gomez DR, et al. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys 2008; 72:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanna EY, Cardenas AD, DeMonte F, et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg 2011; 137:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang JH, Cho SH, Kim JP, et al. Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis. J Oral Maxillofac Surg 2012; 70:1717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Airoldi M, Garzaro M, Valente G, et al. Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology 2009; 76:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Ghanem S, Horowitz G, Abergel A, et al. Elective neck irradiation versus observation in squamous cell carcinoma of the maxillary sinus with N0 neck: A meta-analysis and review of the literature. Head Neck 2015; 37:1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sangal NR, Lee YJ, Brady JS, et al. The role of elective neck dissection in the treatment of maxillary sinus squamous cell carcinoma. Laryngoscope 2018; 128:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galloni C, Locatello LG, Bruno C, et al. The Role of Elective Neck Treatment in the Management of Sinonasal Carcinomas: A Systematic Review of the Literature and a Meta-Analysis. Cancers (Basel) 2021; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers LL, Nussenbaum B, Bradford CR, et al. Paranasal sinus malignancies: an 18-year single institution experience. Laryngoscope 2002; 112:1964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanco AI, Chao KS, Ozyigit G, et al. Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harbo G, Grau C, Bundgaard T, et al. Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients. Acta Oncol 1997; 36:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dulguerov P, Jacobsen MS, Allal AS, et al. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001; 92:3012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dirix P, Nuyts S, Geussens Y, et al. Malignancies of the nasal cavity and paranasal sinuses: long-term outcome with conventional or three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhattacharyya N. Factors affecting survival in maxillary sinus cancer. J Oral Maxillofac Surg 2003; 61:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dutta R, Dubal PM, Svider PF, et al. Sinonasal malignancies: A population-based analysis of site-specific incidence and survival. Laryngoscope 2015; 125:2491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilic S, Kilic SS, Baredes S, et al. Survival, Morbidity, and Quality-of-Life Outcomes for Sinonasal and Ventral Skull Base Malignancies. Otolaryngol Clin North Am 2017; 50:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel ZM, Li J, Chen AY, Ward KC. Determinants of racial differences in survival for sinonasal cancer. Laryngoscope 2016; 126:2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SP, Russell JL, Chen NW, et al. Sinonasal Carcinoma: Racial and Ethnic Disparities in Survival--A Review of 4714 Patients. Otolaryngol Head Neck Surg 2015; 153:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward ML, Kernig M, Willson TJ. HPV-Related Multiphenotypic Sinonasal Carcinoma: A Case Report and Literature Review. Laryngoscope 2021; 131:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contrera KJ, Woody NM, Rahman M, et al. Clinical management of emerging sinonasal malignancies. Head Neck 2020; 42:2202.
          </a>
         </li>
         <li class="breakAll">
          NCCN Guidelines: Treatment by Cancer Type. National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (Accessed on September 18, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo P, Manes RP, Schwam ZG, Judson BL. Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma. Otolaryngol Head Neck Surg 2017; 156:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MN, Konuthula N, Parasher A, et al. Treatment modalities in sinonasal undifferentiated carcinoma: an analysis from the national cancer database. Int Forum Allergy Rhinol 2017; 7:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gamez ME, Lal D, Halyard MY, et al. Outcomes and patterns of failure for sinonasal undifferentiated carcinoma (SNUC): The Mayo Clinic Experience. Head Neck 2017; 39:1819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourad WF, Hauerstock D, Shourbaji RA, et al. Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. Am J Clin Oncol 2013; 36:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chambers KJ, Lehmann AE, Remenschneider A, et al. Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States. J Neurol Surg B Skull Base 2015; 76:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopherson K, Werning JW, Malyapa RS, et al. Radiotherapy for sinonasal undifferentiated carcinoma. Am J Otolaryngol 2014; 35:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Workman AD, Brody RM, Kuan EC, et al. Sinonasal Undifferentiated Carcinoma: A 15-Year Single Institution Experience. J Neurol Surg B Skull Base 2019; 80:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amit M, Abdelmeguid AS, Watcherporn T, et al. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol 2019; 37:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendenhall WM, Hinerman RW, Malyapa RS, et al. Inverted papilloma of the nasal cavity and paranasal sinuses. Am J Clin Oncol 2007; 30:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melroy CT, Senior BA. Benign sinonasal neoplasms: a focus on inverting papilloma. Otolaryngol Clin North Am 2006; 39:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawson W, Patel ZM. The evolution of management for inverted papilloma: an analysis of 200 cases. Otolaryngol Head Neck Surg 2009; 140:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillemaud JP, Witterick IJ. Inverted papilloma of the sphenoid sinus: clinical presentation, management, and systematic review of the literature. Laryngoscope 2009; 119:2466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dragonetti A, Gera R, Sciuto A, et al. Sinonasal inverted papilloma: 84 patients treated by endoscopy and proposal for a new classification. Rhinology 2011; 49:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hausdorff J, Davis E, Long G, et al. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Cancer J Sci Am 1997; 3:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logsdon MD, Ha CS, Kavadi VS, et al. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laskin JJ, Savage KJ, Voss N, et al. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma 2005; 46:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samstein RM, Carvajal RD, Postow MA, et al. Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head Neck 2016; 38:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003; 27:594.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3401 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24935016" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23189751" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Arsenic, metals, fibres, and dusts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10740168" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Malignant neoplasms of the nasal cavity and paranasal sinuses: a series of 256 patients in Mexico City and Monterrey. Is air pollution the missing link?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8256781" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Risk factors for cancers of the nasal cavity and paranasal sinuses among white men in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18201444" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The prevalence of human papilloma virus infection in sinonasal inverted papilloma specimens classified by histological grade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19365846" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17991313" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Correlation of immunophenotype of sinonasal non-Hodgkin's lymphoma to Epstein-Barr virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16629523" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22127982" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24138871" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : International comparisons of the incidence and mortality of sinonasal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18283160" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17127030" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17127030" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15489145" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Imaging of neoplasms of the paranasal sinuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16361146" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Imaging of lumps and bumps in the nose: a review of sinonasal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16361146" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Imaging of lumps and bumps in the nose: a review of sinonasal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24554063" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lymph node metastasis in t4 maxillary sinus squamous cell carcinoma: incidence and treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24554063" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lymph node metastasis in t4 maxillary sinus squamous cell carcinoma: incidence and treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18286492" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Results of endoscopic resection followed by radiotherapy for primarily diagnosed adenocarcinomas of the paranasal sinuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10924968" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10924968" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20737500" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Contemporary management of sinonasal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33756515" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Sinonasal cancers treatments: state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20485042" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Management of clinically negative neck in maxillary carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33544640" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16955762" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Periorbita: computed tomography and magnetic resonance imaging findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18023029" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Management of the orbit in malignant sinonasal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10897104" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Preoperative imaging to predict orbital invasion by tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20502772" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16327559" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Ethmoido-orbital tumors: our experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10890772" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Squamous cell carcinoma of the sinonasal tract invading the orbit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16823871" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Craniofacial resection for tumors of the nasal cavity and paranasal sinuses: a 25-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2000010" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prognostic factors in craniofacial surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8052078" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Factors affecting survival of patients with tumors of the anterior skull base.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9570623" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Studies of the anatomy and pathology of the orbit in carcinoma of the maxillary sinus and their impact on preservation of the eye in maxillectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12172245" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Orbital preservation in surgical management of sinonasal malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18025351" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Sparing the eye in craniofacial surgery for superior nasal vault malignant neoplasms: analysis of benefit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34060523" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Critical review of multidisciplinary approaches for managing sinonasal tumors with orbital involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34439150" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Surgical Management of Sinonasal Cancers: A Comprehensive Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33517131" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Sinonasal cancer encroaching the orbit: Ablation or preservation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33567468" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18493946" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Endoscopic skull base surgery: principles of endonasal oncological surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20096236" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Palliative endoscopic surgery in advanced sinonasal and anterior skull base neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24445501" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Endoscopic resection of sinonasal cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22287429" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Outcome results of endoscopic vs craniofacial resection of sinonasal malignancies: a systematic review and pooled-data analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26972568" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Propensity score analysis of endoscopic and open approaches to malignant paranasal and anterior skull base tumor outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28865090" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sinonasal quality of life after endoscopic resection of malignant sinonasal and skull base tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16510334" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Developments in reconstruction of midface and maxilla.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31477492" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Orbital floor symmetry after maxillectomy and orbital floor reconstruction with individual titanium mesh using computer-assisted navigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11126900" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Combined anterior craniofacial resection for tumors involving the cribriform plate: early postoperative complications and technical considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15825205" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16983689" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Outcome of craniofacial resection in patients 70 years of age and older.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21166570" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Endoscopic endonasal skull base surgery: analysis of complications in the authors' initial 800 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21121816" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : One thousand endoscopic skull base surgical procedures demystifying the infection potential: incidence and description of postoperative meningitis and brain abscesses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10435816" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Conformal radiation therapy treatment planning reduces the dose to the optic structures for patients with tumors of the paranasal sinuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24980873" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30191869" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Definitive Carbon-Ion Radiation Therapy for Locally Advanced Sinonasal Malignant Tumors: Subgroup Analysis of a Multicenter Study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15708266" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Preventing radiation retinopathy with hyperfractionation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17161557" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755554" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12598339" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10439167" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18395361" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21242552" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21945430" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19258726" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24913744" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Elective neck irradiation versus observation in squamous cell carcinoma of the maxillary sinus with N0 neck: A meta-analysis and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29193120" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The role of elective neck dissection in the treatment of maxillary sinus squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33924359" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The Role of Elective Neck Treatment in the Management of Sinonasal Carcinomas: A Systematic Review of the Literature and a Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12439163" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Paranasal sinus malignancies: an 18-year single institution experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15093898" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9090965" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11753979" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17570610" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Malignancies of the nasal cavity and paranasal sinuses: long-term outcome with conventional or three-dimensional conformal radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12966476" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Factors affecting survival in maxillary sinus cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26228792" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Sinonasal malignancies: A population-based analysis of site-specific incidence and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28160996" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Survival, Morbidity, and Quality-of-Life Outcomes for Sinonasal and Ventral Skull Base Malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26915596" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Determinants of racial differences in survival for sinonasal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26163451" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Sinonasal Carcinoma: Racial and Ethnic Disparities in Survival--A Review of 4714 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32159863" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : HPV-Related Multiphenotypic Sinonasal Carcinoma: A Case Report and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32212360" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Clinical management of emerging sinonasal malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32212360" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical management of emerging sinonasal malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27703092" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27717204" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Treatment modalities in sinonasal undifferentiated carcinoma: an analysis from the national cancer database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28561906" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Outcomes and patterns of failure for sinonasal undifferentiated carcinoma (SNUC): The Mayo Clinic Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22992621" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Trimodality management of sinonasal undifferentiated carcinoma and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25844294" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24268566" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Radiotherapy for sinonasal undifferentiated carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30733906" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Sinonasal Undifferentiated Carcinoma: A 15-Year Single Institution Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30615549" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17921720" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Inverted papilloma of the nasal cavity and paranasal sinuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16757234" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Benign sinonasal neoplasms: a focus on inverting papilloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19248937" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The evolution of management for inverted papilloma: an analysis of 200 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19798734" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Inverted papilloma of the sphenoid sinus: clinical presentation, management, and systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21743878" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Sinonasal inverted papilloma: 84 patients treated by endoscopy and proposal for a new classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12576916" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9327155" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9241082" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263574" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27043023" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12717245" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
